|
| 氨磷汀联合GP方案治疗晚期恶性肿瘤的药物经济学评价 |
| Pharmacoeconomic Evaluation of Gemcitabine plus Cisplatin Combined with Amifostine in Treatment of Malignant Tumor |
| |
| DOI： |
| 中文关键词: 氨磷汀 吉西他滨 顺铂 恶性肿瘤 药物经济学 |
| 英文关键词:Amifostine Gemcitabine Cisplatin Malignant tumor Pharmacoeconomics |
| 基金项目:浙江省药学会医院药学科研基金项目（编号：2012ZYY37） |
|
| 摘要点击次数: 1433 |
| 全文下载次数: 1519 |
| 中文摘要: |
| 摘 要 目的:对GP（吉西他滨+顺铂）方案与氨磷汀联合GP方案治疗恶性肿瘤进行成本效果分析，为临床选择化疗方案提供依据。方法：回顾分析79例晚期恶性肿瘤患者的病历资料，按不同化疗方案分为GP组42例，氨磷汀联合GP组37例，比较两组方案的疗效、不良反应及治疗成本，并进行药物经济学评价。结果：GP组与氨磷汀联合GP组的总有效率分别为38.10%和35.14%，差异无统计学意义（P＞0.05）；治疗成本分别为11 807.8元和18 057.4元，成本 效果比分别为309.92和513.87；与GP组不良反应相比，氨磷汀联合GP组的消化道反应发生率明显升高（P＜0.01），低血压发生率增加（P＜0.05）。结论：2个方案的近期疗效相似，氨磷汀联合GP方案的成本更高，且不良反应发生率增加。成本效果分析表明，GP方案更具有经济学优势。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the cost effectiveness of gemcitabine plus cisplatin (GP) combined with amifostine in treatment of malignant tumor compared with GP and provide bias for clinical chemotherapy regimen. Methods:79 cases with malignant tumor were randomly divided into two groups, in which they were treated with GP (n=42) and GP with amifostine (n=37), respectively. The adverse reactions and cost effectiveness in two groups were analyzed and compared with each other by pharmacoeconomic methods.Results:For the GP group and GP with amifostine group, the clinical therapeutic effects were 38.10% and 35.14%, in which there was no significant difference（P＞0.05）. However, the total therapy cost in the groups were 11 807.8 RMB and 18 057.4 RMB, cost effective ratio were 309.92 and 513.87, respectively. And there was a significant increase in the risks of gastrointestinal reaction (P＜0.01) and hypotension (P＜0.05) in GP with amifostine group. Conclusion:The clinical therapeutic effects of the two regimens were similar, while the cost and risk of adverse reactions of GP with amifostine were higher. In consideration of the pharmacoeconomics, the therapeutic regimen with GP was more suitable in treatment of malignant tumor. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
